New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2016

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2018

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Xenon129 MRI imaging

subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

DRUG

Gadolinium MRI

subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

DRUG

Advair (250mcg/50mcg) one puff twice a day

subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Virginia

OTHER

NCT02826343 - New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter